KRBP - Kiromic BioPharma, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
0
0
0
0
0
Operating expenses
Research development
13,928
13,920
11,368
5,053
1,202
Selling general and administrative
20,500
17,194
13,938
14,144
2,504
Total operating expenses
34,428
31,114
25,306
19,197
3,705
Operating income or loss
-34,428
-31,114
-25,306
-19,197
-3,705
Interest expense
12.8
166.5
12.2
3.3
22.5
Total other income/expenses net
-3,858
-3,450
-270.8
-
-
Income before tax
-38,298
-34,731
-25,589
-19,200
-3,728
Income tax expense
-
-
-
-
0
Income from continuing operations
-38,298
-34,731
-25,589
-19,200
-3,728
Net income
-38,298
-34,731
-25,589
-19,200
-3,728
Net income available to common shareholders
-38,643
-35,076
-25,589
-19,913
-3,728
Basic EPS
-
-64.41
-67.81
-132.60
-30.76
Diluted EPS
-
-64.41
-67.81
-132.60
-30.76
Basic average shares
-
544.529
380.607
150.195
129.323
Diluted average shares
-
544.529
380.607
150.195
129.323
EBITDA
-
-32,891
-25,107
-18,997
-3,618